Effect of Fluoride Varnish Formulation on the Management of Dentin Hypersensitivity

NCT ID: NCT07286344

Last Updated: 2025-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-04

Study Completion Date

2026-06-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized controlled clinical trial aims to determine whether different fluoride varnish formulations reduce dentin hypersensitivity (DH) in young adults diagnosed with DH. The primary purpose of this study is to evaluate the clinical effectiveness of two commercially available fluoride varnishes.

The main questions this study aims to answer are:

* Does Clinpro Clear® (aqueous base, 9,500 ppm NaF) lead to a greater reduction in dentin hypersensitivity compared with Duraphat® (rosin/resin base, 22,600 ppm NaF)?
* Do these varnish formulations improve oral health-related quality of life and patient satisfaction?

Researchers will compare a single application of Duraphat® with a single application of Clinpro Clear® to assess differences in hypersensitivity reduction, quality-of-life outcomes, and patient satisfaction.

Participants will:

* Receive one application of either Duraphat® or Clinpro Clear® under standardized clinical conditions.
* Complete baseline and post-treatment evaluations, including:
* Dentin hypersensitivity intensity using a visual analogue scale (VAS)
* Air-blast response using the Schiff scale
* Oral health-related quality of life using the OHIP-14
* Patient satisfaction using the CSAT survey

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fluoride Varnishes Hypersensitivity Dentin

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Dentin hypersensitivity Fluoride varnishes Visual analogue scale (VAS) Schiff scale OHIP-14 Desensitizing agents Aqueous fluoride varnish

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized controlled clinical trial with parallel arms
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Resin/rosin-based varnish, 22,600 ppm NaF (Duraphat® Fluoride Varnish)

Application procedure:

* The tooth surface will be cleaned and saliva gently removed.
* The appropriate amount of varnish will be dispensed onto an application tray.
* The varnish will be applied with a cotton applicator, probe, or brush, forming a thin film.
* The patient will remain seated with lip retractors in place for 15 minutes.
* Patients will be instructed not to brush their teeth or chew hard foods for at least 4 hours post-application.

Group Type ACTIVE_COMPARATOR

Resin/rosin-based varnish, 22,600 ppm NaF

Intervention Type DEVICE

The tooth surface will be cleaned and dried, and the varnish will be dispensed onto an application tray. A thin film will be applied using a cotton applicator, probe, or brush. Patients will remain seated with lip retractors in place for 15 minutes and will be advised to avoid toothbrushing and hard foods for at least 4 hours after application.

Aqueous fluoride varnish, 9,500 ppm NaF (Clinpro Clear® Fluoride Varnish)

Application procedure:

* The tooth surface will be cleaned and dried; a lip retractor will be used.
* The varnish will be expressed fully into the dispensing chamber of the unit-dose package.
* Using the applicator brush, the varnish will be applied to fully cover the hypersensitive area.
* Patients will be instructed not to touch the teeth with the tongue or attempt to remove the varnish.
* After application, patients will remain with lip retractors in place for 15 minutes.

Group Type EXPERIMENTAL

Aqueous fluoride varnish, 9,500 ppm NaF

Intervention Type DEVICE

The tooth surface will be cleaned and dried with a lip retractor in place. The varnish will be dispensed into the unit-dose chamber and applied with a brush to fully cover the hypersensitive area. Patients will be instructed not to disturb the varnish and will remain with the lip retractors in place for 15 minutes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aqueous fluoride varnish, 9,500 ppm NaF

The tooth surface will be cleaned and dried with a lip retractor in place. The varnish will be dispensed into the unit-dose chamber and applied with a brush to fully cover the hypersensitive area. Patients will be instructed not to disturb the varnish and will remain with the lip retractors in place for 15 minutes.

Intervention Type DEVICE

Resin/rosin-based varnish, 22,600 ppm NaF

The tooth surface will be cleaned and dried, and the varnish will be dispensed onto an application tray. A thin film will be applied using a cotton applicator, probe, or brush. Patients will remain seated with lip retractors in place for 15 minutes and will be advised to avoid toothbrushing and hard foods for at least 4 hours after application.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18 and 40 years
* Absence of systemic diseases with oral manifestations or requiring medications with antisialagogue effects
* Fully dentate (excluding third molars or teeth extracted for orthodontic reasons)
* Absence of periodontal disease, or periodontal condition in a stable state
* Presence of at least one cervical lesion with a Schiff sensitivity score ≥ 1
* No previous treatment or restorative procedures on the target lesions (including no topical fluoride application within the last 6 months)

Exclusion Criteria

* Patients requiring long-term use of NSAIDs or other analgesic/anti-inflammatory medications
* Patients with allergy to milk proteins
* Patients with allergy to organic resins or pine-derived substances
* Pregnant or breastfeeding individuals
* Patients with fixed orthodontic appliances in place
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Solventum

INDUSTRY

Sponsor Role collaborator

University of Concepcion, Chile

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michael Wendler Ernst

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sebastian Muñoz, DDS

Role: PRINCIPAL_INVESTIGATOR

Department of Restorative Dentistry, Faculty of Dentistry, Universidad de Concepcion

Michael Wendler, DDS, PhD

Role: STUDY_DIRECTOR

Department of Restorative Dentistry, Faculty of Dentistry, Universidad de Concepcion

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinica de Rehabilitación Avanzada e Implantologia (CRAI)

Concepción, Región del Biobío, Chile

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Chile

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Fernando Zurita, DDS

Role: CONTACT

Phone: +56996403566

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Fernando Zurita, DDS

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Tenuta LMA, Capalbo LC, Yoshino EY. Enamel Fluoride Reactivity of Professional Fluoride Products Is Not Correlated With Their Total Fluoride Content. Pediatr Dent. 2025 May 15;47(3):178-182.

Reference Type RESULT
PMID: 40533917 (View on PubMed)

Sharan A, Pawar B, Bagde H, Chawla TK, Dhan AV, Shyamsukha B, Sharma S. Comparative Evaluation of Dentin Hypersensitivity Reduction Over One Month after a Single Topical Application of Three Different Materials: A Prospective Experimental Study. J Pharm Bioallied Sci. 2024 Dec;16(Suppl 4):S3405-S3407. doi: 10.4103/jpbs.jpbs_848_24. Epub 2024 Oct 29.

Reference Type RESULT
PMID: 39926954 (View on PubMed)

Sgreccia PC, Dame-Teixeira N, Barbosa RES, Araujo PF, Zanatta RF, Garcia FCP. Assessment of the Oral Health Impact Profile (OHIP-14) improvement of different treatments for dentin hypersensitivity in noncarious cervical lesions-a randomized clinical study. Clin Oral Investig. 2022 Nov;26(11):6583-6591. doi: 10.1007/s00784-022-04610-x. Epub 2022 Jul 7.

Reference Type RESULT
PMID: 35796800 (View on PubMed)

Porto IC, Andrade AK, Montes MA. Diagnosis and treatment of dentinal hypersensitivity. J Oral Sci. 2009 Sep;51(3):323-32. doi: 10.2334/josnusd.51.323.

Reference Type RESULT
PMID: 19776498 (View on PubMed)

Machado AC, Maximiano V, Yoshida ML, Freitas JG, Mendes FM, Aranha ACC, Scaramucci T. Efficacy of a calcium-phosphate/fluoride varnish and ionomeric sealant on cervical dentin hypersensitivity: A randomized, double-blind, placebo-controlled clinical study. J Oral Rehabil. 2022 Jan;49(1):62-70. doi: 10.1111/joor.13270. Epub 2021 Nov 2.

Reference Type RESULT
PMID: 34676918 (View on PubMed)

Lopez R, Baelum V. Spanish version of the Oral Health Impact Profile (OHIP-Sp). BMC Oral Health. 2006 Jul 7;6:11. doi: 10.1186/1472-6831-6-11.

Reference Type RESULT
PMID: 16827940 (View on PubMed)

Garofalo SA, Sakae LO, Machado AC, Cunha SR, Zezell DM, Scaramucci T, Aranha AC. In Vitro Effect of Innovative Desensitizing Agents on Dentin Tubule Occlusion and Erosive Wear. Oper Dent. 2019 Mar/Apr;44(2):168-177. doi: 10.2341/17-284-L. Epub 2018 Jun 28.

Reference Type RESULT
PMID: 29953338 (View on PubMed)

Fernandez CE, Tenuta LM, Zarate P, Cury JA. Insoluble NaF in Duraphat(R) may prolong fluoride reactivity of varnish retained on dental surfaces. Braz Dent J. 2014;25(2):160-4. doi: 10.1590/0103-6440201302405.

Reference Type RESULT
PMID: 25140722 (View on PubMed)

Douglas-de-Oliveira DW, Vitor GP, Silveira JO, Martins CC, Costa FO, Cota LOM. Effect of dentin hypersensitivity treatment on oral health related quality of life - A systematic review and meta-analysis. J Dent. 2018 Apr;71:1-8. doi: 10.1016/j.jdent.2017.12.007. Epub 2017 Dec 17.

Reference Type RESULT
PMID: 29262305 (View on PubMed)

Dall Agnol MA, Battiston C, Tenuta LMA, Cury JA. Fluoride Formed on Enamel by Fluoride Varnish or Gel Application: A Randomized Controlled Clinical Trial. Caries Res. 2022;56(1):73-80. doi: 10.1159/000521454. Epub 2021 Dec 13.

Reference Type RESULT
PMID: 34915485 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CEC-SSC 25-10-120

Identifier Type: -

Identifier Source: org_study_id